Featured Publications
[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, Burkemper J, Wright BD, Frye J, Frye S, Siegel BA, Dehdashti F. [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Molecular Imaging And Biology 2016, 18: 952-959. PMID: 27146421, PMCID: PMC5096950, DOI: 10.1007/s11307-016-0951-z.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerDose-limiting organPositron emission tomographyBreast cancerMSv/MBqOptimal imaging timeHuman radiation dosimetryPET/CT imagesOrgan time activity curvesGreater tumorTime-activity curvesPurposeThe purposeHuman dosimetryEmission tomographyBiodistribution dataEffective dosePatientsAdverse effectsCancerLiverImaging parametersWomenPresent studyTomographyDays
2019
Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy
Massicano AVF, Lee S, Crenshaw BK, Aweda TA, Sayed R, Super I, Bose R, Marquez-Nostra BV, Lapi SE. Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy. Cancer Biotherapy & Radiopharmaceuticals 2019, 34: 209-217. PMID: 30676778, PMCID: PMC7227434, DOI: 10.1089/cbr.2018.2654.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAnimalsAntibodies, Monoclonal, HumanizedBreast NeoplasmsCell Line, TumorDeferoxamineFemaleHumansIsothiocyanatesMaytansineMiceMice, NudePositron Emission Tomography Computed TomographyRadioisotopesRadiopharmaceuticalsReceptor, ErbB-2TrastuzumabTreatment OutcomeTumor BurdenXenograft Model Antitumor AssaysX-Ray MicrotomographyZirconiumConceptsT-DM1 therapyBreast cancerTumor volumeHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2BT-474 tumorsGrowth factor receptor 2HER2-positive tumorsFactor receptor 2HER2 expressionBCa patientsReceptor 2TherapyTumorsEarly responseBetter delineationPertuzumabPoor delineationMBq/MiceTreatmentResponsePatientsHER2
2018
Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer
Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA. Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Research And Treatment 2018, 169: 523-530. PMID: 29442264, PMCID: PMC5955803, DOI: 10.1007/s10549-018-4696-z.Peer-Reviewed Original ResearchAdultAgedBiomarkers, TumorBiopsyBreast NeoplasmsFemaleHumansImage Processing, Computer-AssistedMiddle AgedMultimodal ImagingNeoplasm GradingNeoplasm StagingPositron Emission Tomography Computed TomographyRadioisotopesRadiopharmaceuticalsReceptor, ErbB-2ROC CurveSensitivity and SpecificityTrastuzumabZirconiumTargeting HER2 in Nuclear Medicine for Imaging and Therapy
Massicano AVF, Marquez-Nostra BV, Lapi SE. Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Molecular Imaging 2018, 17: 1536012117745386. PMID: 29357745, PMCID: PMC5784567, DOI: 10.1177/1536012117745386.BooksConceptsHuman epidermal growth factor 2HER2 expressionHER2 statusEpidermal growth factor 2Treatment of patientsHER2-positive cancersWhole-body assessmentStandard diagnostic techniquesMetastatic settingGrowth factor 2Breast cancerClinical studiesNuclear medicineTumor fociInvasive biopsyAlternative treatmentTime of analysisSmall sample sizeTherapyNuclear imagingBiopsyPatientsFactor 2TumorsCancer